Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study

NCT06649422 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Lymphocytic, Acute, Adult

Interventions

DRUG: Blinatumomab

Sponsor

Shandong University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]